Chuangyebang learned that Ningbo Haiershi Gene Technology Co., Ltd. (hereinafter referred to as “Hairshi Gene”) announced that it has received hundreds of millions of yuan in Series C financing, led by Shenzhen Venture Capital, Boyuan Capital, Hefeng Venture Capital, and Yingong Venture Capital. And Binjiang started to vote and followed the vote. Previously, the company’s last round of financing also received exclusive investment from industrial investor Jinhe Capital. This round of financing will be mainly used for new technology exploration and product development.
Founded in August 2011, Hersh Gene is committed to becoming the most distinctive provider of complete medical testing solutions. The company focuses on the two major business areas of clinical diagnosis and forensic science, and provides comprehensive medical testing application solutions covering molecular diagnosis, immunodiagnosis, and biochemical diagnosis for medical institutions at all levels, disease control centers, etc., as well as human DNA for public security systems and judicial institutions. Complete technical solutions such as individual identification and kinship identification.
In recent years, under the background of the encouragement of national policies, the improvement of people’s health awareness, and the continuous expansion of medical needs, the market size of China’s IVD market has grown rapidly, the old market structure has been broken, new market vitality has been stimulated, and domestic brands have ushered in innovative development. new opportunities. In the next 5-10 years, the in vitro diagnostic market will gradually complete import substitution and move towards a pattern of full competition among domestic brands.
Looking at the present and the future, from the technical point of view, the clinical application of test methodology will be a complementary scenario, and it is difficult to establish long-term advantages by relying on a single technology and single product. China is a country with a large population, and no application field is a small market. Molecular diagnostic technology will continue to be applied to more fields in the future, surpassing traditional biochemical diagnosis and immunodiagnosis, and becoming the technology with the largest market share in in vitro diagnosis.
The close combination of innovative technology and clinical application is the outstanding capability advantage of Hersh Gene R&D. It is worth noting that in 2011, Hersch Gene began to proactively deploy molecular diagnostic multiple nucleic acid detection technology. Based on the uniqueness and innovation of its technology, it has launched thirteen respiratory pathogen multiplex detection in the fields of respiratory pathogen detection and HPV detection. The leading products that fill the market gap, such as test kits (Ruisibei) and human papilloma (HPV) typing test kits with E6/E7 oncogene as the detection site. In terms of the integrated layout strategy, Hersch Gene has moved faster, and has formed a complete solution for medical testing by coordinating the layout around molecular diagnosis, biochemical diagnosis and immunodiagnosis.
Mr. Yu Ding, chairman and general manager of Haiershi Gene, said: “First of all, I am very grateful for the recognition and support of new and old shareholders, who have accompanied the company to grow rapidly in the IVD industry. The company continues to deepen the development and clinical application of molecular diagnostic multiple nucleic acid detection technology. Further expand the product and technology layout, and create overall solutions in the fields of molecular diagnosis, immunoluminescence, biochemical diagnosis and other medical tests.”
Mr. Zhou Yi, general manager of Shenzhen Venture Capital Hongtu Medical Fund, said: “Hairsch Gene has long been committed to the independent development of innovative in vitro diagnostic technologies, especially in the field of multiple nucleic acid detection, providing multiple sets of overall solutions. We very much recognize the team’s innovative ability, The market development experience and the company’s industrial strategy layout will continue to support the company and its team to focus on products and technologies in the future, and promote the company to become an industry leader.”
Mr. Hao Bixi, the founding shareholder of Jinhe Capital, said: “Haiershi Gene takes independent innovation as its core capability and has a complete IVD product line layout. It is a high-growth enterprise in the industry. We are very optimistic about the company’s technological heritage and development ideas, and will continue to use The ecological advantage of the fund industry empowers Hersh Gene and helps the company become a more well-known national brand in the industry.”
Mr. Tao Feng, founding partner of Boyuan Capital, said: “After the first investment in 2020, Boyuan Capital will continue to make additional additions this round. We very much recognize the concept of ‘making society safer and making life healthier’ and the pursuit of excellence. Product quality. Haiershi Gene has deep technical accumulation in the field of multiple nucleic acid detection, and we look forward to the company’s team to achieve breakthroughs in more application fields, and we are willing to work with outstanding enterprises.”
Mr. Zheng Run, Investment Director of Hefeng Venture Capital, said: “We have been following Hersh Gene for many years. The company has been deeply involved in the in vitro diagnostic industry, and has leveraged its unique advantages in multiple molecular diagnostic technology in the field of precision medicine. We believe that the success of this round of financing can Help the company to accelerate the cultivation in the field of intelligent manufacturing and accelerate the high-quality development of the enterprise.”
Mr. Li Shuai, General Manager of Yingong Venture Capital, said: “Based on the unique advantages of its own platform in the multi-joint inspection solution, Harsh Gene has developed and provided high-performance diagnostic products for the fields of clinical medicine, forensic science and public safety. We are optimistic about Hersh Gene Technology becoming a leading company in this field.”
Mr. Fang Liping, general manager of Binjiang Kaitou Investment, said: “Hairsch Gene focuses on R&D and technological innovation, and continuously expands application fields around core technologies. We are very happy to cooperate with Hiersch Gene to accelerate the transformation of corporate technological achievements. We are full of confidence in the company!”
media coverage
Yiou Entrepreneurship State Investment China Network
Related events
- Haiershi Gene received hundreds of millions of yuan in Series C financing2022-08-08
- Haier Zhijia’s registered capital increased to 9 billion yuan2021-01-19
- Haier Smart Home plans to be listed in Hong Kong tomorrow2020-12-20
- Haier Smart Home released “Smart Home Space Classification and Design Guidelines” 2020-12-18
- Haier Smart Home submitted an IPO application to the Hong Kong Stock Exchange, with a profit of 3.6 billion yuan in the first half of the year2020-09-11
This article is reprinted from: https://readhub.cn/topic/8ij2f6U1jce
This site is for inclusion only, and the copyright belongs to the original author.